Accellent first quarter net sales increase 1.3% to $131.6 million

NewsGuard 100/100 Score

Accellent Inc. (the "Company" or "Accellent"), a wholly owned subsidiary of Accellent Holdings Corp., today announced results for its fiscal first quarter ended March 31, 2012.    

First Quarter 2012 Financial Results

Net sales increased 1.3% to $131.6 million in the first quarter of 2012 compared with $129.9 million in the first quarter of 2011. Income from operations was $11.0 million in the first quarter of 2012, compared with $13.0 million in the first quarter of 2011. Net loss was $7.0 million in the first quarter of 2012, compared with a net loss of $8.2 million in the first quarter of 2011.

Adjusted EBITDA for the first quarter of 2012 was $23.0 million, or 17.5% of net sales, compared to Adjusted EBITDA of $23.8 million, or 18.4% of net sales, in the first quarter of 2011.

"We returned to year over year top-line growth in the first quarter, despite a continued soft market," stated Donald Spence, President and CEO of Accellent. "Revenue increased 1.3% in the first quarter; however our profitability declined compared to last year. I remain optimistic that we are creating the necessary changes in our business to succeed both in today's challenging market and also in the long-term."

Source:

Accellent Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.